EDRN Prostate MRI Biomarker Study

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan
Study ID
NCT03784924
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRI prostate — DIAGNOSTIC_TEST
    MRI and laboratory biomarkers

Study Details

The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.

Key Dates

Start date
Feb 4, 2019
Status verified
Jan 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
950 participants (estimated)

Arms

  • Arm: Initial prostate biopsy
    Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.

Primary Outcome Measure

Clinically significant prostate cancer [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MichiganAnn ArborMichigan48109
John T Wei, MD
[email protected]
7346153040
Rabia Martin
[email protected]
7347637508

Find similar trials in Ann Arbor, MI

By condition
Psoriatic arthritisProstate cancer
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disordersOncologyProstate oncologyMen's healthUrology
By research site
University of Michigan· Ann Arbor, MI

Related Studies